Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Leukemia, Myeloid, Acute 14Myelodysplastic Syndromes 6Advanced Solid Tumors 5Advanced Solid Tumour 4Small Cell Lung Carcinoma 3Recurrence 3Myeloproliferative Disorders 3Leukemia, Myelomonocytic, Chronic 3Carcinoma, Non-Small-Cell Lung 3Neoplasm Metastasis 2Multiple Myeloma 2Esophageal Squamous Cell Carcinoma 2Advanced Solid Tumor 2Advanced Breast Cancer 2Unresectable Locally Recurrent Breast Cancer 1Squamous Cell Carcinoma of Head and Neck 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Ovarian Neoplasms 1Non-small Lung Cancer 1Non-Muscle Invasive Bladder Neoplasms 1Neuroma 1Neoplasms 1Nasopharyngeal Carcinoma 1Multiple Sclerosis 1Metastatic Solid Tumors 1Lung Neoplasms 1Leukemia, Myeloid, Accelerated Phase 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Monocytic, Acute 1Leukemia, Biphenotypic, Acute 1

Interventions

trastuzumab deruxtecan 1Injections 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unresectable Locally Recurrent Breast Cancer × Injections × 30 days × Clear all
NCT07497386 2026-05-11

A Trial of Trastuzumab Rezetecan in Unresectable Locally Recurrent/Metastatic Breast Cancer

Jiangsu HengRui Medicine Co., Ltd.

Phase 2 Recruiting
150 enrolled
Breast

Unresectable Locally Recurrent Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡